<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Brakke Consulting&#x306E;&#x30A6;&#x30A7;&#x30D6;&#x30B5;&#x30A4;&#x30C8;</provider_name><provider_url>https://brakkeconsulting.com/ja</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="VnsJoDnvBL"&gt;&lt;a href="https://brakkeconsulting.com/ja/14077/"&gt;2006 &#x5E74; 8 &#x6708; 25 &#x65E5;&#x306E;&#x52D5;&#x7269;&#x5065;&#x5EB7;&#x30CB;&#x30E5;&#x30FC;&#x30B9;&#x3068;&#x30CE;&#x30FC;&#x30C8;&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/ja/14077/embed/#?secret=VnsJoDnvBL" width="600" height="338" title="&#x201C;Animal Health News &amp; Notes for August 25, 2006&#x201D; &#x2014; Brakke Consulting Website" data-secret="VnsJoDnvBL" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>printer friendly version ******************************************************************* Brakke Consulting&rsquo;s Animal Health News &amp; Notes for August 25, 2006 Copyright &copy; Brakke Consulting, Inc. &nbsp; Editor: Lynn Fondon, DVM, MBA ******************************************************************* IN THE NEWS: &nbsp; earnings news Dainippon Sumitomo Nestle Smithfield Swift Synbiotics Teva (IVX/Abic) Webster &nbsp; &nbsp; other news Alstoe Bramton Genitrix Gold Kist Intervet (Zilmax) Intervet (Vista) Pilgrims Pride Tame Products &nbsp; &nbsp; ******************************************************************* COMPANY EARNINGS RELEASES &nbsp; &gt; Dainippon Sumitomo Pharma reported a decline in net sales of its animal science division, in fiscal 2005 ending March 31, 2006. Sales decreased by 3.3% to YEN 26.4 billion (US$249 million) compared with last year. The company said that the decrease was mainly due to the termination of its distribution agreement with Merial Japan on small animal products, including Cardomec (ivermectin) and Enacard (enalapril), in 2004. (Animal Pharm)&nbsp;&nbsp; &nbsp; &gt; Synbiotics Corporation announced that it recorded a 7% increase in revenues for the first six months of 2006 compared with the same period in 2005.&nbsp; Revenues for the first six months totaled $10.8 million compared with $101 million for the same period last year.&nbsp; Sales growth was led by the company&rsquo;s avian influenza line. (company press release)&nbsp;&nbsp; &nbsp; &gt; Teva reported that revenues for its animal health business were $78 million for the first half of 2006.&nbsp; Teva&rsquo;s animal health business includes IVXView Full Post;</description></oembed>
